clinical trial · NCT06534502
Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures
SeizuresSeizures, FocalSeizure, Partial OnsetSeizure Disorder, PartialSeizure, PartialEpilepsies, PartialEpilepsyZonisamide Oral Product
brief summary
The purpose of this research is to determine the optimal dose, safety and tolerability of zonisamide oral suspension in children ages 1 month to 17 years of age who have partial-onset (focal) seizures. The study consists of four periods: a Screening Period (about 14 days), a Titration Period (8 weeks), a Maintenance Period (4 weeks), and a Follow-Up Period (1 week).
started
Sep 1, 2026
primary completion
Sep 1, 2027
completion
Sep 1, 2027
last updated
Jun 4, 2026
official title
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Zonisamide Oral Suspension (100 mg/5 ml) to Determine a Dosing Regimen in Children 1 Month to 17 Years of Age With Partial-onset Seizures
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol